A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
Status:
Completed
Trial end date:
2016-04-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4
study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a
lower severity of flu-like symptoms (FLS) as compared to the evening administration, in
subjects with relapsing multiple sclerosis (RMS).